Core Insights - Teva Pharmaceutical Industries Ltd. has received FDA approval for its biosimilar Ponlimsi, which is a competitor to Amgen's Prolia, aimed at treating various bone conditions [1][8] - The approval is based on evidence demonstrating that Ponlimsi has similar efficacy, safety, and immune response as Prolia [1] - Teva anticipates that the approval will significantly enhance its biosimilar portfolio [3] Product Details - Ponlimsi is approved for all indications of Prolia, including treatment for osteoporosis in high-risk men and postmenopausal women, glucocorticoid-induced osteoporosis, and improving bone mass in certain cancer patients [2] - The biosimilar versions of Prolia and Xgeva were previously approved in the European Union in November 2025, with Prolia generating sales of $4.4 billion in the same year, accounting for 13% of Amgen's total product sales [3][11] Financial Outlook - Teva aims to grow its biosimilars business by $400 million by 2027, with expectations for improvement in its generics business as well [8][13] - The company's global generics business was flat in 2025 compared to 2024, but it is projected to rise in a low single-digit range in 2026 [12][13] Market Performance - Year-to-date, Teva's shares have decreased by 9.2%, while the industry has seen a decline of 8.7% [5]

Core Viewpoint - Alvotech has filed its Annual Report 2025 with the U.S. Securities and Exchange Commission, highlighting its commitment to transparency and regulatory compliance [1]. Company Overview - Alvotech is a biotechnology company focused on developing and manufacturing biosimilar medicines globally [2]. - The company aims to be a leader in the biosimilars market by providing high-quality, cost-effective products through a fully integrated approach and extensive in-house capabilities [2]. - Alvotech has five biosimilars approved and marketed in various global markets, including those for Humira®, Stelara®, Simponi®, Eylea®, and Prolia®/Xgeva® [2]. - The current development pipeline includes nine disclosed biosimilar candidates targeting autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [2]. - Alvotech has established strategic commercial partnerships to enhance its global reach and leverage local expertise across markets such as the United States, Europe, Japan, China, and parts of South America, Africa, and the Middle East [2].

Core Viewpoint - Alvotech has filed its Annual Report 2025 with the SEC, highlighting its commitment to transparency and regulatory compliance [1]. Company Overview - Alvotech is a biotechnology company focused on developing and manufacturing biosimilar medicines globally [2]. - The company aims to be a leader in the biosimilars market by providing high-quality, cost-effective products through a fully integrated approach [2]. - Alvotech has five biosimilars approved and marketed in various global markets, including those for Humira, Stelara, Simponi, Eylea, and Prolia/Xgeva [2]. - The current development pipeline includes nine disclosed biosimilar candidates targeting autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [2]. - Alvotech has established strategic commercial partnerships to enhance its global reach and leverage local expertise across multiple regions, including the U.S., Europe, Japan, China, and parts of South America, Africa, and the Middle East [2].

Core Viewpoint - Alvotech has published its Annual Report for 2025, highlighting its focus on the development and manufacture of biosimilar medicines, with a commitment to becoming a global leader in this sector [1]. Company Overview - Alvotech is a biotechnology company founded by Robert Wessman, dedicated to developing and manufacturing biosimilar medicines for patients worldwide [2]. - The company aims to deliver high-quality, cost-effective products and services through a fully integrated approach and broad in-house capabilities [2]. - Alvotech has five biosimilars approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept), and Prolia®/Xgeva® (denosumab) [2]. - The current development pipeline includes nine disclosed biosimilar candidates targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer [2]. - Alvotech has established a network of strategic commercial partnerships to enhance its global reach and leverage local expertise in various markets, including the United States, Europe, Japan, China, and parts of South America, Africa, and the Middle East [2].

Core Insights - Teva Pharmaceutical Industries Ltd. has achieved significant milestones in its biosimilar portfolio, including FDA approval for PONLIMSI (denosumab-adet) as a biosimilar to Prolia and acceptance of applications for a proposed biosimilar candidate to Xolair (omalizumab) by both the U.S. FDA and the European Medicines Agency (EMA) [1][2][3] Group 1: PONLIMSI FDA Approval - The FDA approval of PONLIMSI is based on comprehensive evidence demonstrating similar efficacy, safety, and immunogenicity to Prolia, covering all indications of the reference product [2][3] - PONLIMSI is indicated for various conditions, including treatment of postmenopausal women with osteoporosis at high risk for fracture and increasing bone mass in men with osteoporosis [7][10][11] Group 2: Xolair Biosimilar Candidate - Teva's proposed biosimilar candidate to Xolair includes a Biologics License Application (BLA) to the U.S. FDA and a Marketing Authorization Application (MAA) to the EMA, covering all indications approved for Xolair [4][37] - The applications are supported by a robust data package demonstrating efficacy, safety, and immunogenicity similar to Xolair [4] Group 3: Strategic Growth and Expertise - Teva's biosimilars R&D engine showcases depth and maturity, combining internal expertise with strategic partnerships to build a competitive portfolio [2][3] - The company aims to address patient needs and drive long-term growth through its expanding global biosimilar portfolio [2][3]

Financial Data and Key Metrics Changes - Total revenues for 2025 increased by 21% year-on-year to $593 million, with adjusted EBITDA rising by 27% to $137 million, representing a margin of 23% [36][37] - In Q4 2025, total revenues were up 13% year-on-year at $173 million, with licensing revenues accounting for 75% of the total [34][36] - Gross margin for the year finished at 61%, while Q4 gross margin was 66% [34][36] Business Line Data and Key Metrics Changes - Product revenues were driven by commercial momentum for the Humira biosimilar AVT02 and the Stelara biosimilar AVT04, which launched in the U.S. in Q1 2025 [36] - Product sales in Q4 were softer at $43 million, with a negative product margin of 37% due to timing of orders and planned facility upgrades [34][35] - The company has 30 biosimilars in development, representing over $185 billion in global sales potential [9][27] Market Data and Key Metrics Changes - In the U.S. market, Humira's originator share declined from approximately 70% at the beginning of 2025 to around 45% by year-end, indicating a shift towards biosimilars [18] - SIMLANDI holds about 9% of the U.S. market, making it the second-largest and one of the fastest-growing biosimilars in its segment [19] - In Europe, Uzpruvo has established a leading position with over 20% share of the biosimilar segment [19] Company Strategy and Development Direction - The company aims to strengthen its operational platform and expand its manufacturing footprint, including dual sourcing initiatives to enhance supply resilience [15][16] - Alvotech is focused on advancing its biosimilar portfolio towards approval and commercialization, particularly in the U.S. market [45][46] - The company anticipates continued growth in the biosimilar market, driven by the expected loss of patent protection for over 100 biologics in the next decade [7][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to address regulatory observations and expects to resubmit applications to the FDA in the second quarter of 2026 [4][26] - The company is positioned to benefit from recent FDA guidance that reduces the need for large efficacy trials, thereby lowering development costs and timelines [8][30] - The outlook for 2026 is reaffirmed with expected revenues in the range of $650-$700 million, reflecting continued double-digit sales growth [42][44] Other Important Information - The company raised close to $300 million from capital markets to support ongoing investments in development programs and manufacturing [17] - Alvotech's shares were listed on Nasdaq Stockholm, enhancing access to Nordic and European investors [17] Q&A Session Summary Question: U.S. approvals and pending items - Management confirmed completion of remediation efforts and is compiling information to support the upcoming submission, aiming for the first half of 2026 [49] Question: Guidance for 2026 - The lower end of the guidance does not include revenues from U.S. launches, while the upper end reflects potential growth from existing approvals [50][56] Question: Incremental commercial approvals needed - The guidance is based on momentum from existing approvals, with no new approvals factored in [56] Question: Manufacturing platform expansion - The company is evolving its dual sourcing strategy, with expected developments in the first half of the year [57] Question: Competitive landscape and risk mitigation - Management emphasized the importance of being first to market and strategic IP positioning to mitigate competitive exposure [68][69]

Financial Data and Key Metrics Changes - In 2025, total revenues increased by 20% to $591 million, while adjusted EBITDA rose by 27% to $137 million, reflecting strong financial performance [9][36] - For Q4 2025, total revenues were up 13% year-on-year at $173 million, with licensing revenues constituting 75% of the total [34][36] - The gross margin for the year was 61%, driven by the mix of licensing revenues [36] Business Line Data and Key Metrics Changes - The company has 30 biosimilars in development, representing over $185 billion in global sales potential [9][27] - Product revenues were $43 million in Q4 2025, with a negative product margin of 37% due to timing of orders and planned facility upgrades [34] - The commercial momentum for biosimilars like AVT02 and AVT04 is expected to continue into 2026, with AVT02 holding a 9% market share in the U.S. [75] Market Data and Key Metrics Changes - In the U.S. market, the originator of Humira held approximately 70% at the beginning of 2025, which declined to around 45% by year-end, indicating a shift towards biosimilars [18] - SIMLANDI has captured about 9% of the U.S. market, making it one of the fastest-growing biosimilars [19] - In Europe, Uzpruvo has established a leading position with over 20% share of the biosimilar segment [19] Company Strategy and Development Direction - The company aims to strengthen its operational platform and expand its manufacturing capabilities, including dual sourcing initiatives [5][15] - Alvotech is focused on advancing its biosimilar portfolio towards approval and commercialization, particularly in the U.S. market [45] - The company anticipates significant opportunities in the biosimilar market due to over 100 biologics expected to lose patent protection in the next decade [7][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in addressing regulatory observations from the FDA and expects to resubmit applications in Q2 2026 [4][26] - The company is well-positioned to benefit from recent FDA guidance that reduces the need for large efficacy trials, thus lowering development costs [8][30] - The outlook for 2026 is reaffirmed with expected revenues between $650 million and $700 million, reflecting continued double-digit growth [42] Other Important Information - The company raised close to $300 million from capital markets to support ongoing investments in development and manufacturing [17] - Alvotech's shares were listed on Nasdaq Stockholm, enhancing its presence in the Nordic and European markets [17] Q&A Session Summary Question: U.S. approvals and pending items - Management confirmed completion of remediation efforts and is compiling information to support the upcoming submission, aiming for the end of Q1 or early Q2 2026 [49] Question: Guidance for 2026 - The lower end of the revenue guidance does not include U.S. launch revenues, while the upper end reflects aspirations including potential U.S. launches [50][56] Question: Incremental commercial approvals needed - The guidance is based on momentum from existing approvals, with no new approvals factored in for the lower end of the range [56] Question: Manufacturing platform expansion - The expansion is expected to occur in the first half of 2026, with costs aligned with anticipated R&D expenditures [57] Question: Competitive landscape and risk mitigation - Management emphasized the importance of being first to market and strategic IP positioning to mitigate competitive exposure [68]

Financial Data and Key Metrics Changes - In 2025, total revenues increased by 20% to $591 million, while adjusted EBITDA rose by 27% to $137 million, reflecting strong financial performance [9][38] - For Q4 2025, total revenues were up 13% year-on-year at $173 million, with licensing revenues comprising 75% of the total [36][38] - The gross margin for the year was 61%, driven by the mix of licensing revenues [38] Business Line Data and Key Metrics Changes - The company has 30 biosimilars in development, representing over $185 billion in global sales potential [9][28] - Product revenues were driven by commercial momentum for the Humira biosimilar AVT02 and the Stelara biosimilar AVT04, which launched in the U.S. in Q1 2025 [38] - AVT-02 and AVT-04 are expected to continue growing, with AVT-02 holding approximately 9% of the U.S. market [19][76] Market Data and Key Metrics Changes - In the U.S. market, the originator of Humira held roughly 70% at the beginning of 2025, which declined to around 45% by year-end, indicating a shift towards biosimilars [18] - In Europe, the biosimilar Uzpruvo has established a leading position with over 20% share of the biosimilar segment [19] - The U.S. biosimilar market now accounts for approximately 40% of the total market, with continued growth expected [19] Company Strategy and Development Direction - The company aims to strengthen its operational platform and expand its manufacturing footprint, including dual sourcing initiatives [5][14] - Alvotech is focused on advancing its biosimilar portfolio towards approval and commercialization, particularly in the U.S. market [47] - The company anticipates significant opportunities in the biosimilar market due to over 100 biologics expected to lose patent protection in the next decade [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to address regulatory observations and expects to resubmit applications to the FDA in Q2 2026 [4][27] - The company is well-positioned to benefit from recent FDA guidance changes that reduce the need for large efficacy trials, thus lowering development costs [8][32] - The outlook for 2026 is reaffirmed with expected revenues in the range of $650-$700 million, reflecting continued double-digit sales growth [44] Other Important Information - The company raised close to $300 million from capital markets to support ongoing investments in development and manufacturing [17] - Alvotech's shares were listed on Nasdaq Stockholm, enhancing its presence in the Nordic and European markets [17] Q&A Session Summary Question: Status of U.S. approvals and pending items - The company completed its remediation efforts and is compiling information to demonstrate effectiveness before submission, aiming for the first half of 2026 [51][52] Question: Guidance for 2026 and U.S. product assumptions - The lower end of the 2026 revenue guidance does not include revenues from U.S. launches, while the upper end reflects aspirations for growth [53][56] Question: Incremental commercial approvals needed for guidance - The guidance is based on momentum from existing approvals, with no new approvals built into the lower end of the range [58] Question: Expansion of manufacturing platform and associated costs - The dual sourcing initiative is expected to be secured in the first half of 2026, with costs anticipated to align with existing R&D expenditure [59][60] Question: Competitive landscape and mitigation strategies - The company aims to be first to market with its biosimilars, leveraging strategic IP positioning and partnerships to mitigate competitive exposure [68][69] Question: Sales trends for AVT02 and growth expectations - The company anticipates continued growth for AVT02 and AVT04, despite some challenges in the European market [75][76]

Full Year and Q4 2025 Earnings Presentation 19 MARCH 2026 z z Disclaimer This presentation ("Presentation") does not contain or constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of Alvotech (the "Company") to any person in the United States or in any jurisdiction to whom or in which such offer or solicitation is unlawful. Any trademarks, servicemarks, trade names and copyrights of the Company and other companies contained in this Presentation are th ...

Summary of Amgen Conference Call Company Overview - **Company**: Amgen - **Key Personnel**: Peter Griffith (CFO), Casey (IR), Jasper van Grunsven (Rare Disease) Core Industry Insights - **Strong Portfolio Performance**: In 2025, Amgen reported strong momentum with 13 products delivering double-digit growth, 14 products exceeding $1 billion in annual sales, and 18 products achieving record performance [7][8][21] - **Key Growth Drivers**: The growth is supported by six key drivers: Repatha, Evenity, Tezspire, rare disease portfolio, innovative oncology, and biosimilars [7][8][14] - **Rare Disease Portfolio**: Generated $5 billion in sales in 2025, up 14% year-over-year, with significant contributions from UPLIZNA, which grew 73% [8][35] Financial Highlights - **Revenue and Earnings Growth**: Double-digit growth in both revenue and earnings per share in 2025 [7] - **Biosimilars Performance**: The biosimilars portfolio generated $3 billion in product sales in 2025, growing 37% year-over-year, with strong uptake of Pavblu [9][18] - **Quarterly Expectations**: Anticipated seasonal Q1 headwinds due to insurance cycles and historical sales patterns for certain products [12][13] Product-Specific Insights - **UPLIZNA**: - Significant growth driven by new patient acquisition and geographic expansion [8][35] - Expected continued growth with new indications and ongoing studies in autoimmune diseases [8][38] - **Innovative Oncology**: - IMDELLTRA has become a standard of care in small cell lung cancer, with ongoing Phase 3 studies [9][17] - Xaluritamig is being evaluated for metastatic castrate-resistant prostate cancer [9] - **MariTide**: - Positioned as a differentiated treatment for obesity and related conditions, with six global Phase 3 studies underway [10][28] - Monthly dosing is expected to improve patient adherence and long-term outcomes [76][78] Competitive Landscape - **Market Positioning**: Amgen is focused on maintaining a competitive edge in the obesity market against formidable competitors like Lilly and Novo [80] - **M&A Strategy**: Amgen is open to mergers and acquisitions, focusing on innovation and effective integration to enhance shareholder value [85][86] Future Outlook - **Pipeline Development**: 2026 is expected to be a year of disciplined data generation across multiple Phase 2 and Phase 3 programs [10][11] - **Long-Term Growth**: Amgen is well-positioned for sustained long-term growth with a diversified portfolio and a strong pipeline [13][22] Additional Considerations - **Adherence Challenges**: Current treatment burdens and dosing frequencies are barriers to long-term persistence on therapy, which MariTide aims to address [76][78] - **Safety Profile of DAS**: Dazodalibep is engineered to avoid adverse events seen in previous therapies targeting the same pathway, with a favorable safety profile observed in Phase 2 studies [64][66] This summary encapsulates the key points discussed during the Amgen conference call, highlighting the company's performance, product insights, financial outlook, and strategic positioning within the industry.